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Introduction
The prostanoid prostacyclin (prostaglandin (PG) I 2 ) plays a central role in haemostasis acting as a potent inhibitor of platelet aggregation and as an endothelium-derived vasodilator 1; 2 . The actions of prostacyclin generally counteract those of thromboxane (TX) A 2 , a potent vasoconstrictor released principally by platelets, implying that factors regulating their relative levels and /or cellular responses are central to haemostasis and vessel tone 2; 3; 4 . Alterations in the relative levels of TXA 2 and prostacyclin or of their specific receptors contribute to a variety of vascular dysfunctions including thrombosis, stroke, systemic and pulmonary hypertensions, myocardial infarction and atherosclerosis 5; 6; 7 . Prostacyclin also imparts an important cardioprotective role 8 ; it inhibits leukocyte-endothelial cell interaction 9 and promotes enhanced endothelial cell survival and/or proliferation supporting neovascularization and angiogenesis 10 .
Prostacyclin and its analogues have been used clinically to improve pulmonary hypertension and various vaso-occlusive disorders such as that associated with Raynaud's syndrome and Buerger's disease 1; 11; 12 .
As a major product of cyclooxygenase (COX)-2 catalyzed metabolism of arachidonic acid, prostacyclin acts as a potent pro-inflammatory mediator and is abundantly produced during myocardial ischemia and hypoxia offering cytoprotection 13; 14; 15 . Moreover, the critical role of prostacyclin to vascular integrity has been further highlighted through clinical findings that certain COXIBs, the subclass of nonsteroidal anti-inflammatory drugs designed to selectively inhibit COX-2, depress prostacyclin generation predisposing patients to increased risk of thrombotic stroke and myocardial infarction 16 . Whilst mice deficient in prostacyclin receptors (IP -/-) display normal vascular function, they show enhanced thrombotic tendency in response to endothelium damage, for example 14; 17 . Significantly however, IP -/null mice display altered pain perception and, in models of acute inflammation, exhibit substantially reduced inflammatory responses consistent with the central role of prostacyclin in nociception and as a potent proinflammatory agent 14; 17; 18 .
Prostacyclin mediates its actions through activation of its signature prostacyclin receptor, IP, a member of the G protein coupled receptor (GPCR) superfamily that is widely expressed within the vasculature including in platelets/megakaryocytes, macrophages, vascular endothelial and smooth muscle, in sensory neurons of the dorsal root ganglion and in various tissues such as in thymus, lung, heart and spleen 2; 17; 18 . While the IP is primarily coupled to activation of adenylyl cyclase (AC), mediating prostacyclininhibition of platelet aggregation and vascular tone, it may also regulate a number of other secondary effector systems, perhaps in a tissue-and /or species-specific manner 2; 19 . The cloned mouse (m) and human (h) IPs couple to both G S and to G q /phospholipase Cβ activation and to intracellular calcium ([Ca 2+ ] i ) mobilization, while megakarocytopoiesis of 1 o h.stem cells is associated with reductions in prostacyclin-induced [Ca 2+ ] i mobilization due to loss of Gα 16 and increased Gα S expression 20 . In addition to coupling to G s , the mIP, but not the hIP, couples to G i and to G q activation through a novel G protein switching mechanism, involving direct cAMP dependent protein kinase (PK) A-phosphorylation of the IP within its carboxyl terminal tail domain 21; 22 . A number of independent studies have established that the IP is subject to agonist-induced desensitization and down-regulation in human platelets and other cell types, providing an important mechanism of fine-tuning the cellular responses to prostacyclin in vivo 23; 24; 25; 26; 27 . While the hIP undergoes agonist-induced protein kinase (PK)C phosphorylation, desensitizing its signalling 27 , its internalization is entirely independent of both PKC and of the classic GRK/β-arrestin-mediated mechanism 26 but, rather, largely occurs through a mechanism involving its direct interaction with Rab5a 28 .
Despite these studies and the wealth of information that has been accrued relating to the basic mechanisms of intracellular signalling by the IP 2; 19; 21; 29 , coupled to the breadth of knowledge highlighting the critical role of the prostacyclin in haemostasis, inflammation and pain 9; 14; 16; 30 , surprisingly to date the hIP gene remains largely uncharacterized and the factors regulating its expression have not been identified 31 .
This study aims to address this scientific deficit by characterizing the hIP gene, focusing primarily on delineation of the mechanism determining its expression within the vasculature. Herein, we have identified a critical role for evolutionary conserved Sp1, PU.1 and Oct-1 cis-acting elements in the transcriptional coregulation of the hIP in the megakaryocytic human erythroleukemia (HEL) 92.1.7 32 and in human endothelial EA.hy 926 33 cell lines. These studies represent the first detailed characterization of the human IP promoter and provide a strong molecular and genetic basis for understanding the modes of regulation of IP gene expression in health and disease.
Results

Functional Characterisation of the human Prostacyclin Receptor Promoter in human erythroleukemia cells
The central role of prostacyclin, signalling through its cognate prostacyclin receptor (IP), in haemostasis and vascular disease in addition to its role in inflammation, pain and analgesia is widely recognized 1; 2; 34 . However, the factors regulating expression of the IP gene in humans, or indeed in other species, have not been investigated in detail. Hence, the key aim of the current study was to identify the critical cis-acting elements and trans-acting factors regulating basal expression of the IP in the human erythroleukemia (HEL) 92.1.7 cell line and in human vascular endothelial cells. Through previous investigations, the structural organisation of the human IP gene was elucidated and the major transcription initiation (TI) site utilized in human lung tissue mapped to approximately nucleotide -875, relative to the translation start codon (+1) 35 . Consistent with those studies, herein the major TI was also investigated and was localized to a region between -875 to -774 in HEL 92.1.7 cells (data not shown). Hence, for subsequent studies herein, the human prostacyclin receptor promoter (PrmIP) is defined as nucleotides -2427 to -774, relative to the translational start codon (+1) and is located approximately 1.5 kb -0.1 kb 5' and 3', respectively, of the major TI site at -875 35 .
Initially, genetic reporter assays employing firefly luciferase as specific reporter were used to characterise the PrmIP aiming to identify the major regulatory regions therein. Recombinant pGL3Basic only marginally greater than that directed by the promoter-less pGL3B vector.
Collectively, these data suggest that the -1022 to -895 region, proximal to the TI, within the PrmIP represents the core promoter containing the positive regulatory elements required to direct efficient basal transcription in HEL cells while it also contains an upstream repressor sequence (URS) located between -1502 and -1271. Hence, the PrmIP6 (-1022 to -774) represents the smallest sub-fragment generated herein that contains the proximal core promoter. Consistent with that hypothesis, 3' deletion of nucleotides spanning -1022 to -774 to generate 3'∆PrmIP (Figure 1; Panel B ) almost completely abolished PrmIPdirected transcriptional activity in HEL cells such that the level of luciferase activity was not substantially different from the empty pGL3B vector (compare 0.303 ± 0.05 vs 0.145 ± 0.01 RLU, respectively).
Identification of Functional Sp1, PU.1 and Oct-1 Elements within the PrmIP.
Thereafter, it was sought to identify the key cis-acting elements located between -1022 and -895 within the PrmIP6 sub-fragment responsible for directing basal transcription from the core proximal promoter.
Amongst the putative elements identified through bioinformatic analysis 36 were a consensus Sp1 (-967) element and closely positioned PU box 37 (-954, herein referred to as a PU.1 element) and octamer-binding (-949) elements (Figure 2; panel A) . Furthermore, bioinformatic analysis revealed that the putative Sp1, PU.1 box and octamer sites are evolutionary conserved within the proximal IP promoters from a host of other species including those of horse, dog, bovine (Figure 8B) , mouse and rat (data not shown).
Disruption of the Sp1 element (GGGCGG to GGATGG) through site-directed mutagenesis (SDM) resulted in a 2-fold reduction (p < 0.0001) in luciferase expression compared to that directed by PrmIP6 (Figure 2 ; Panel A). Mutation of the PU.1 element (GAGGAA to GACGAA) also led to a 2-fold (p < 0.0001) reduction in luciferase activity relative to that of PrmIP6. Similarly, disruption of the octamer element (AAATGA to AACTGA) at -949 led to a 1.3-fold (p = 0.0143) reduction in PrmIP6-directed luciferase expression, albeit to a lesser extent than disruption of either the Sp1 (p = 0.0002) or PU.1 (p = 0.0015) elements alone.
A number of independent studies suggest that octamer sequence elements within certain promoters may be specifically regulated either by the ubiquitous Oct-1 38 or by the B lymphocyte-and/or neuronespecific Oct-2 39; 40 or, in the certain cases, by both Oct-1 and Oct-2 41; 42 . Hence, herein, the specificity of Oct-1 or Oct-2 binding to the octamer binding site within the PrmIP was investigated by examining the effect of heterologous over-expression of hemagglutinin (HA)-tagged forms of Oct-1 and Oct-2 on luciferase reporter expression. Western blot analysis confirmed that both Oct-1 and Oct-2 were over-expressed to equivalent levels in the transfected HEL cells (Figure 2 ; Panel C). However, ectopic expression of Oct-1, but not Oct-2, led to a significant increase in PrmIP6-directed luciferase activity (p < 0.0001 and p = 0.1071, respectively; Figure 2: Panel B) .
The Ets family of transcription factors are characterised by an evolutionary-conserved DNA-binding domain that binds to a purine-rich GGAA/T core sequence with additional flanking nucleotides often determining specificity 43 . Within PrmIP, a conserved putative PU.1 element 37 was identified (5'-GAGGAA-3') suggesting that the Ets family member PU.1 may be involved in hIP regulation. However, many family members, including PU.1, Fli1 and Ets-1, have been reported to play important roles in megakaryocytic and erythroid differentiation 44 . Therefore, the specificity of the PU box within PrmIP was also investigated by examining the effect of heterologous over-expression of PU.1, Fli-1 and Ets-1, on luciferase reporter expression. Immunoblot analysis confirmed that PU.1, Fli1 and Ets-1 were over-expressed to equivalent levels in the transfected HEL cells (Figure 2 ; Panel E). Ectopic expression of PU.1 led to a significant increase in PrmIP6-directed luciferase activity (p < 0.0001). Similary, over-expression of Fli-1 resulted in a significant increase in PrmIP6-directed luciferase activity (p = 0.043), albeit to a lesser extent than ectopic expression of PU.1. Ets-1 heterologous over-expression did not significantly effect PrmIPdirected luciferase activity (p = 0.342, respectively; Figure 2D&E ). Hence, collectively these data confirm that disruption of the Sp1, PU.1 and octamer elements each significantly impaired PrmIP6-directed transcription, and the putative octamer site at -949 is preferentially regulated by Oct-1, as opposed to Oct-2, and the putative Ets element is preferentially regulated by PU.1 and/or Fli1, but not Ets-1, in HEL cells.
Electromobility Shift Assays and Chromatin Immunoprecipitations to investigate Sp1, PU.1 and Oct-1
Binding.
Electromobility shift assays (EMSAs) and antibody supershift assays were then employed to Furthermore, to investigate whether Sp1 actually binds to the IP promoter in vivo, chromatin immunoprecipitation (ChIP) assays were performed using chromatin extracted from HEL cells and antibodies directed to endogenous Sp1. PCR analysis using primers specific for the -1271 to -774 region of PrmIP generated amplicons from both the input chromatin and from the anti-Sp1, but not the normal rabbit IgG, immunoprecipitated chromatin ( Figure 3C) . Conversely, as additional controls, PCR analysis using primers for another region of the PrmIP, namely -1901 to -1555, only generated an amplicon from the input chromatin but not from the normal rabbit IgG or anti-Sp1 immunoprecipitated chromatin ( Figure 3D ).
Hence, EMSA/supershift assays demonstrate that Sp1 specifically binds to the Sp1 probe in vitro while ChIP assays establish that Sp1 occupies elements within the -1271 to -774 region of the PrmIP chromatin in vivo.
Collectively, these data show that we have identified a consensus Sp1 transcription factor binding site at -967 that is critical for efficient basal human PrmIP-directed gene expression in HEL cells.
Nuclear factor binding to the proposed PU.1 and Oct-1 elements was also investigated by EMSA and Figure 4B) . With respect to the other Ets family members, while no supershift occurred with antibodies directed to Ets-1, a weak supershifted immune complex was evident with the anti-Fli1 sera, suggesting that Fli1 has the capability of binding to the PU.1 element within PrmIP, albeit to a lesser extent than PU.1.
To investigate whether endogenous Oct-1, PU.1, Fli1 and/or Ets-1 actually bind to the IP promoter in vivo, ChIP analysis was performed using the specific anti-Oct-1, anti-PU.1, anti-Fli1 and anti-Ets-1 antibodies and normal rabbit IgG as a background control. Immunoprecipitation of the cross-linked chromatin fragments obtained from HEL cells followed by semi-quantitative PCR using primers specific for the -1271 to -774 region of PrmIP surrounding the putative PU.1 site (-954) and Oct-1 (-949) elements generated amplicons from both the anti-Oct-1 (Figure 4G ) and anti-PU.1 (Figure 4H ), but not from the anti-Fli1, anti-Ets-1 or control IgG immunoprecipitates ( Figure 4H) . Additionally, PCR analysis using primers for a non-specific region of PrmIP (-1901 to -1555) generated an amplicon from the input chromatin, no products were generated from the anti-Oct-1, anti-PU.1, anti-Fli1 or anti-Ets-1 immunoprecipitated chromatin ( Figure 4I ). Hence, these data confirm that both Oct-1 and PU.1, but not Fli1 or Ets-1, can specifically bind to the PrmIP promoter region of HEL cell chromatin located between -1271 to -774.
Examination of the Co-Regulation of the human IP promoter by Sp1, PU.1 and Oct-1 Transcription
Factors in HEL cells
Hence, studies herein have established that Sp1, PU.1 and Oct-1 specifically bind to the proximal PrmIP core region to regulate basal transcription of the hIP gene in HEL cells. In order to investigate whether Sp1, PU.1 and Oct-1 act independently or synergistically to regulate PrmIP-directed gene expression in HEL cells, the effect of mutating the cis-acting elements in combination was next examined (Figure 5) .
Initially, the double combinations, namely PrmIP6 Sp1/Pu1* , PrmIP6 Sp1/Oct1* and PrmIP6 Pu1/Oct1* , were generated and their ability to direct luciferase expression relative to that of the corresponding PrmIP6 subfragment containing wild type or singly mutated Sp1, PU.1 or Oct-1 elements was examined ( Figure 5 ). While the PrmIP6 Sp1/Pu1* subfragment containing an intact Oct-1 element retained the ability to direct luciferase expression, the level of expression was some 3.2-fold less than that directed by the wild type PrmIP6 (p < 0.0001). Moreover, luciferase expression directed by the PrmIP6 Sp1/Pu1* was 1.7-fold (p < 0.001) and 1.6fold (p < 0.0005) less than that directed by the PrmIP6 Sp1* and PrmIP6 Pu1* , respectively. Hence, these data suggest that both Sp1 and PU.1 elements can independently regulate PrmIP-directed gene expression in HEL cells and that disruption of both elements generates a promoter with a substantially impaired ability to initiate transcription through the Oct-1 element.
Consistent with this, the PrmIP6 Sp1/Oct1* and PrmIP6 Pu1/Oct1* subfragments containing intact Pu.1 and Sp1 elements, respectively, retained the ability to direct luciferase expression but with levels of expression reduced by some 2-fold (p < 0.0001) and 2-fold (p < 0.0001) relative to the wild type PrmIP6, respectively ( Figure 5) . Noteworthy, the level of luciferase expression directed by either the PrmIP6 Sp1/Oct1* and PrmIP6 Pu1/Oct1* subfragments was not significantly different than that directed by the PrmIP6 Sp1* (p = 0.6486) or PrmIP6 PU.1* (p = 0.9185), respectively. However, both PrmIP6 Sp1/Oct1* and PrmIP6 Pu1/Oct1* subfragments were significantly reduced relative to that directed by PrmIP6 Oct1* (p = 0.006 and p = 0.011, respectively).
These data suggest that both the Sp1 and PU.1 elements play a more significant role in PrmIP6-directed gene expression than that of Oct-1.
Disruption of all three cis-acting elements further impaired PrmIP-directed transcriptional activity such that PrmIP6 Sp1/Pu1/Oct1* -directed expression was reduced 6-fold (p < 0.0001) relative to PrmIP6 ( Figure   5 ). Moreover, the fact that transcriptional activity of PrmIP6 Sp1/Pu1/Oct1* was reduced relative to that of the double mutant PrmIP6 Sp1/Pu1* (2-fold; p = 0.0034) further confirms a role for Oct-1. Collectively, these data reveal that the three Sp1, PU.1 and Oct-1 transcription factors act independently to co-regulate PrmIPdirected gene expression in the megakaryocytic HEL 92.1.7 cell line. While the subfragment PrmIP6 Sp1/PU.1* , containing an intact Oct-1 element, retained the ability to direct luciferase expression, its level of expression was some 4.7-fold reduced relative to that directed by the wild type PrmIP6 (p < 0.0001). Furthermore, luciferase expression directed by PrmIP6 Sp1/PU.1* relative to either singly mutated PrmIP6 Sp1* or PrmIP6 PU.1* subfragments was reduced by some 1.7-fold in both cases (p = 0.021 and p = 0.0073, respectively).
Luciferase expression directed by the PrmIP6 Sp1/Oct-1* and PrmIP6 PU.1/Oct-1* subfragments containing intact PU.1 and Sp1 elements was reduced in each case by 4-fold (p < 0.0008) and 3.2-fold (p < 0.0003), respectively, relative to wild type PrmIP6 (Figure 6B) . The level of luciferase expression directed by either the PrmIP6 Sp1/Oct-1* or PrmIP6 PU.1/Oct-1* subfragments was not significantly different than that directed by PrmIP6 Sp1* (p = 0.1167) or PrmIP6 PU.1* (p = 0.2773), respectively. However, expression by both PrmIP6 Sp1/Oct-1* and PrmIP6 PU.1/Oct-1* subfragments were significantly reduced relative to that of PrmIP6 Oct-1* (p = 0.0009 and p = 0.0148, respectively). These data confirm that Sp1, PU.1 and Oct-1 independently regulate PrmIP and, consistent with the findings in HEL cells, provide further evidence that Sp1 and PU.1 impart a more significant role than that of Oct-1.
Furthermore, disruption of all three cis-acting elements almost completely abolished PrmIP6 Sp1/PU.1/Oct-1* -directed transcriptional activity yielding a 7-fold reduction in luciferase activity relative to the wild type PrmIP6 (p = 0.0001). Moreover, transcriptional activity directed by PrmIP6 Sp1/PU.1/Oct-1* was reduced relative to that of PrmIP6 Sp1/PU.1* (1.5-fold; p = 0.0246) further confirming a role for Oct-1 in endothelial cells.
To investigate whether endogenous Sp1, PU.1 and Oct-1 actually bind to the IP promoter in EA.hy 926 cells in vivo, ChIP analysis was performed using specific anti-Sp1, anti-PU.1 and anti-Oct-1 antibodies and normal rabbit IgG as a background control. Immunoprecipitation of the cross-linked chromatin fragments from EA.hy 926 cells followed by semi-quantitative PCR using specific primers for the -1271 to -744 region of PrmIP surrounding the putative Sp1 (-967), PU.1 (-954) and Oct-1 (-949) elements generated amplicons from each of the anti-Sp1, anti-PU.1 and anti-Oct-1 immunoprecipitates, but not from the IgG control ( Figure 6G; Upper panel) . In order to confirm the specificity of PU.1 binding within PrmIP6 in EA.hy 926 cells, ChIP analysis was also performed using antibodies directed to Fli-1 and Ets-1. While PCR amplicons were generated from the input chromatin, no products were generated from the anti-Fli-1, anti-Ets-1 or the control IgG immunoprecipitates (Figure 6G; Upper panel) . Additionally, PCR analysis using primers for a non-specific region of PrmIP (-1901 to -1555) generated an amplicon in the case of input chromatin only but not from the anti-Sp1, anti-PU.1, anti-Fli1, anti-Ets-1 or anti-Oct-1 immunoprecipitated chromatin ( Figure 6G ; Lower panel). These data confirm Sp1, Pu.1 and Oct-1, but not Fli-1 and Ets-1, can specifically bind to the PrmIP promoter region, between -1271 to -774, of chromatin in EA.hy 926 cells, consistent with the findings in HEL cells. Collectively, these data suggest that Sp1. PU.1 and Oct-1 coregulate PrmIP-directed gene expression in EA.hy 926 cells but that while ectopic expression of Fli1 can mediate an increase in PrmIP-directed reporter gene expression, it does not bind to chromatin in vivo.
Effect of Sp1, PU.1 and Oct-1 on PrmIP-directed Luciferase Activity and hIP mRNA expression.
Thereafter, it was also sought to establish whether ectopic expression of Sp1, PU.1 or Oct-1 could induce changes in PrmIP-directed gene expression and in the levels of endogenous IP mRNA expression in either HEL 92.1.7 or endothelial EA.hy 926 cell lines. Initially, western blot analysis confirmed over-expression of Sp1, PU.1 and Oct-1 in transfected HEL and EA.hy 926 cells (Figure 7 : Panel A-C, insets). Expression of Sp1 significantly increased PrmIP6-directed luciferase activity in HEL and EA.hy 926 cells (p = 0.0016 and p = 0.0006, respectively). Similarly, over-expression of PU.1 and Oct-1 also led to significant increases in PrmIP6-directed expression in both HEL and EA.hy 926 cell lines (p = 0.0044, p = 0.0001, p < 0.0001 and p = 0.0013, respectively; 
Discussion
The actions of prostacyclin generally counteract those of TXA 2 within the vasculature, where it serves as an important endothelium-derived anti-thrombotic and vasodilatory agent to regulate platelet aggregation and blood vessel tone 2; 4 . Alterations in the levels of prostacyclin or of its synthase or its receptor, the IP, have been associated to a range of vascular diseases including thrombosis, unstable angina, systemic and pulmonary hypertension 1; 34 . As a major product of COX-2, prostacyclin is also an essential pro-inflammatory mediator and, from studies initially generated in IP -/null mice, is now widely regarded as a critical autocoid involved in the neurotransmission of pain 34 . However, despite the recognized role of prostacyclin in haemostasis, inflammation and nociception, the factors regulating expression of its target receptor, namely the IP, remains almost completely unexplored and unknown. The aim of the current study was to characterize the human IP promoter with the objective of identifying the essential cis-acting elements and trans-acting factors that determine its basal expression within the vasculature. To this end, HEL 92.1.7 and endothelial EA.hy 926 cells were employed as model platelet -progenitor megakaryocytic and vascular endothelial cells, respectively.
The human IP promoter (PrmIP) is defined herein as the 1.5 kb -0.1 kb region 5' and 3' of the major transcription initiation (TI) site, identified at -875, and lacks a conventional TATA-box and initiator (Inr) element 35 . Successive 5' deletion of PrmIP (-2427 to -774, relative to the translational initiation codon at +1) localized the core promoter to a 248 bp region (-1022 to -774) surrounding the major TI at -875 35 while an upstream repressor sequence (URS) was also identified between -1502 and -1271 within PrmIP.
Upstream repressor and activator sequences are gene-specific sequences that can fine-tune the rate of transcription initiation contributing to the regulation of gene expression 47 . While the identity of the transacting factor(s) that bind and modulate the URS uncovered herein within PrmIP is currently unknown, being the subject of on-going investigations, it is possible that they may play a role in regulating its expression in response to various stimuli and/or in a cell-or tissue-specific manner.
As stated, both 5' and 3'-gene deletions localized the core promoter to the PrmIP6 subfragment (-1022 to -774) and hence it contains the essential core elements required for basal transcription in both HEL and EA.hy 926 cell lines. In TATA-less promoters, assembly of the pre-initiation complex relies on the binding of multiple general transcription factors in proximity to the TI site 48 . Sp1 is a ubiquitously expressed transcription factor and can serve to attract key protein components of the basal transcriptional machinery to a promoter in the absence of a TATA-box 49 . The identification of direct interactions between Sp1, TATA-box binding protein (TBP) and TBP-associated factors (TAFs) led to the suggested role for Sp1 as an anchor for TAFs in TATA-less promoters whereby one or more Sp1 molecules bind to G/C rich regions in such promoters to help establish a transcription pre-initiation complex 50; 51; 52 . Herein, bioinformatic analysis revealed the presence of an evolutionary conserved GC-rich box (5'-ggagGGCGgggc-3'), predicted to be a putative Sp1 binding element, localized some 90 bp 5' of the major TI within the PrmIP. Disruption of the Sp1 element significantly reduced PrmIP6-directed expression in both HEL and EA.hy 926 cell lines. Furthermore, EMSA and supershift assays confirmed the formation of a specific Sp1/DNA complex in vitro in HEL cells. ChIP analysis, using fragmented chromatin from HEL cells and antibodies directed to endogenous Sp1, was consistent with the formation of a direct Sp1/DNA interaction within the basal regulatory region of PrmIP in vivo. Furthermore, ectopic over-expression of Sp1 led to a significant increase in PrmIP6-directed gene expression and hIP mRNA transcript levels. Collectively, these data demonstrate that Sp1 serves as a trans-acting factor critical in the basal regulation of human IP and, from studies in HEL cells, it occurs through a mechanism involving direct DNA/protein interactions. It is possible, or indeed likely, that in the absence of a TATA-element, Sp1 is acting as an initiator within the PrmIP during the formation of the basal pre-initiation complex.
In addition to the Sp1 element, a putative PU.1/Ets binding element was also identified within PrmIP6. The Ets family of transcription factors are known to play roles in a variety of cellular processes such as differentiation, apoptosis and development 44 and are characterised by an evolutionary-conserved DNAbinding domain that binds to a purine-rich GGAA/T core sequence in cooperation with other transcriptional factors and co-factors 43 . Fli1 is a member of the Ets family and was originally isolated from the proviral intergration site of friend murine leukaemia virus-induced mouse erythroleukemia cells and it is preferentially expressed in the hematopoietic cell lineages and vascular endothelial cells 43 . Fli1 has been shown to be involved in the expression of various megakaryocytic genes such as GPVI 53 , GPIX and GPIbalpha 54 . The PU.1 member of the Ets family 44 is a product of the Spi-1 proto-oncogene first identified as the integration site of the friend murine erythroleukemia virus 55 . PU.1 acts as a master regulator of myloid and B cell development 56 and is critical for hematopoietic development particularly during early differentiation of myeloid, erythroid, and B lineage cells 57; 58 . PU.1 has also been shown to regulate certain TATA-less promoters such as c-fes 59 and M-CSF receptor 60 . Given the fact that PU.1 binds to TBP in vitro, it is also thought to recruit TF II D followed by other components of the basal transcriptional machinery 61 . Herein, significant reductions in PrmIP6-directed gene expression were observed upon disruption of the PU.1 element while heterologous over-expression of PU.1 and Fli1, but not Ets-1, yielded significant increases in PrmIP6-directed gene expression in both HEL and EA.hy 926 cell lines. EMSAs established that PU.1 was capable of binding to the PU.1 element in PrmIP6 in HEL cells whereby a specific consensus PU.1 competitor efficiently competed out DNA/protein complex 2, while antibody supershifts established that both PU.1 and, to a lesser extent, Fli1 but not Ets-1 generated retarded immune complexes.
Superseding these findings, the specificity of PU.1 binding was also confirmed in vivo in HEL and EA.hy shown to regulate megakaryocyte-specific genes, such as in the case of the thrombopoietin, GPIX and GP1balpha, their promoters each contain multiple binding sites for GATA-1, a well characterized zinc finger transcription factor important for both erythroid and megakaryocytic differentiation 54; 62 . In those cases, physical interactions between Fli1 and GATA-1 mediate synergistic expression 54; 62 . Bioinformatic analysis of the PrmIP sequence from both humans and a host of other species suggests that it does not contain a GATA-1 binding element, possibly accounting for why Fli1 does not bind to the PU box in vivo, as assessed by ChIP analysis, even though it has the capacity to recognise it in vitro, as assessed by the antibody supershift assays.
Ets family members are often, if not always, found as subunits of multiprotein transcription complexes which are thought to be involved in the fine regulation of cellular promoter/enhancer sequences 63 . Physical and functional interactions of PU.1 with partner proteins, in particular Sp1 family members, are critical to its role in gene expression and lineage determination 64 . Within the PrmIP, the Sp1 and PU.1 elements lie in close proximity (within ~ 20 bp of each other) and therefore it is possible that they interact to co-regulate human IP expression. Consistent with this, simultaneous disruption of both the Sp1 and PU.1 elements generated a promoter PrmIP Sp1,PU.1* with a substantially impaired ability to initiate transcription.
Ets family and Sp1 transcription factors are known to co-transactivate several promoters, including the human T cell lymphotropic virus type 1 (HTLV-1) promoter and the immune coagulant fgl2/fibroleukin promoter 65; 66 . In the context of megakaryocytes, somewhat similar to the PrmIP, the TATA-less integrin αIIb promoter is co-regulated by Sp1 and Ets binding to elements that lie proximal to its TI site and it is proposed that such regulation by Sp1 and Ets serves as a model for megakaryocyte-specific gene expression 67 . Whilst the finding that Sp1 and PU.1 are critical for the regulation of PrmIP within HEL cells is indeed consistent with the latter, we found a similar co-dependence within the endothelial EA.hy 926 cells suggesting that they also act outside of myeloid lineages to regulate IP expression. Moreover, it is also indeed worth noting that in the context of inflammation, PU.1 plays an essential role in the transcriptional upregulation of COX-2 in response to lipopolysaccharide in macrophages 68 . Hence, it is indeed plausible that PU.1 may have a role in the co-ordinate upregulation of prostacyclin synthesis, through COX-2, and signalling, through the IP, such as in response to bacterial sepsis.
Octamer binding proteins belong to the POU (Pit-Oct-Unc) family of transcription factors that play critical roles in the regulation of gene expression in multiple cell types 69 . Two POU domain proteins, the ubiquitously expressed Oct-1 and the lymphoid-specific Oct-2, have been shown to be involved in haematopoietic differentiation 70 . Herein, disruption of the putative octamer element significantly reduced PrmIP6-directed reporter gene expression in HEL and EA.hy 926 cells. Moreover, eptopic expression of Oct-1 and Oct-2 showed preferential upregulation of PrmIP6-directed gene expression by Oct-1 in HEL cells, as opposed to Oct-2. Consistent with these findings, over-expression of Oct-1 also led to a significant increase in PrmIP6-directed gene expression in EA.hy 926 cells. Specific Oct-1 binding was also demonstrated by EMSAs whereby a specific Oct-1 oligonucleotide efficiently competed out two (C1 & C3) of the C1-C3 complexes generated using the over-lapping Pu.1/Oct-1 probe. The identity of the slower migrating C1 complex is unknown but it is possible that it represents a tertiary PU.1/Oct-1/DNA complex.
In the presence of the anti-Oct-1 antibody, a supershifted complex was generated confirming direct Oct-1/DNA binding in vitro. However, superseding the EMSA and supershift assays, ChIP analysis using specific antibody directed to endogenous Oct-1 confirmed that it specifically binds in vivo to the chromatin encoding the basal regulatory region of the human IP promoter in HEL cells. RT-PCR analysis further confirmed an important regulatory role for Oct-1 in both HEL and EA.hy 926 cells whereby ectopic overexpression of Oct-1 yielded an increase in hIP mRNA transcript levels. Hence, these data reveal an important role for the Oct-1 in PrmIP-directed transcriptional activity in megakaryocytic HEL and endothelial EA.hy 926 cells.
Consistent with this hypothesis, cooperative interactions between Oct-1 with either Sp1 or PU.2 have been reported on other RNA polymerase II -regulated promoters. Chen et al., (1996) (Figure 8; Panel B) , rat and mice (data not shown). Coupled to this, the fact that Sp1, PU.1 and Oct-1 were found to be critical in regulating the PrmIP not only in the megakaryocytic HEL 92.1.7 cells, but also in the endothelial EA.hy 926 cell lines, suggests that they provide a general, rather than a cell-or species-specific, model for transcriptional regulation of the IP. It is likely that other upstream regulatory regions, such as the URS and other cis-acting elements, are responsible for the tissue-specific or altered expression of the IP such as in response to inflammation, pain or vascular disease.
This study provides an important molecular and genetic platform that should provide a basis for understanding how the many and diverse responses to prostacyclin are regulated at the level of transcription of the IP gene itself.
Experimental Procedures
Materials pGL3Basic, pRL-Thymidine Kinase (pRL-TK) and Dual Luciferase® Reporter Assay System were obtained from Promega Corporation. DMRIE-C® was from Invitrogen Life Technologies. Anti-Oct-1 (sc-232x), anti-Sp1 (sc-59x), anti-PU.1 (sc-22805x), anti Fli1 (sc-236x), anti-Ets.1 (sc-350x) and normal rabbit IgG (sc-2027) were obtained from Santa Cruz Biotechnology.
Generation of Luciferase-based Genetic Reporter Plasmids
The human prostacyclin receptor (IP) promoter (PrmIP), defined as nucleotides -2427 to -774 located 5' of the translational ATG initiation codon, designated +1, was subcloned into the KpnI -HindIII sites of pGL3Basic to generate pGL3B:PrmIP. To identify sequence elements required for PrmIP activity, a series of 5'-and 3'-deletion subfragments were subcloned into pGL3Basic (pGL3b). Specifically, for all 5' deletions, PCR fragments were generated using the antisense primer Kin274 (5'-dCTCTCAAGCTTCTCTCCAGTCTTGCCCAGGCTC-3′, complementary to nucleotides -807 to -774
where the underlined sequence corresponds to the HindIII cloning site) in combination with specific sense primers designed to amplify progressively shorter regions of PrmIP. The list below identifies the recombinant plasmids encoding 5' deletion fragments of PrmIP generated in pGL3Basic, as well as the identity, sequence and corresponding nucleotides (Nu) of the specific sense primer used for each fragment.
In each case, the -designation indicates nucleotides 5' of the translational start site (designated +1) and underlined sequences represent the KpnI cloning site.
(1) pGL3B:PrmIP1 (primer Kin534; 5′-dGAGAGGTACCCAGCGGTGGTGGCTTGGCTGTG-3′, Nu -1761 to -1739).
(2) pGL3B:PrmIP2 (primer Kin535; 5′-dGAGAGGTACCGATCAAAATATGATTCCTGAAGG-3′, Nu -1682 to -1662). For the 3' deletion, a PCR fragment was generated using pGL3B:PrmIP as template and primers Kin296 (5′-dGAGAGACGCGTAGCTACTCGGGAGGCTGAGGCAC -3′; Νu -2812 to -2778) and Kin532 (5′-dGAGAAAGCTTCAATCCAGGACATCCATCTC -3′; Nu -1022 to -992) and was subcloned into the MluI-HindIII sites of pGL3Basic to generate pGL3B:3′∆PrmIP. The identity and fidelity of all recombinant plasmids was verified by DNA sequence analysis.
Site-directed Mutagenesis
Site-directed mutagenesis (SDM) was carried out using the Quik-Change TM method (Stratagene). The identities of the PrmIP elements subjected to SDM, with their starting positions in brackets, the nucleotides that were changed in underlined bold, templates used and names of the corresponding plasmids generated, as well as the identity, sequence and corresponding nucleotides of the specific primers used are listed below.
1. Sp1 (-967), from gGGCGg to gGATGg using template pGL3B:PrmIP6 to generate pGL3B:PrmIP6 Sp1* . Primers Kin595 (5'-dGGAGAACAGTGAGGGAGGATGGGGCAGAGAGAGG-3') and complementary Kin596. The fidelity of all plasmids was confirmed by DNA sequence analysis.
Cell Culture
Human erythroleukemic (HEL) 92.1.7 cells, obtained from the American Type Culture Collection, were cultured in RPMI 1640, 10 % fetal bovine serum. Human endothelium cells EA.hy 926 cells 45 were obtained from the Tissue Culture Facility at UNC Lineberger Comprehensive Cancer Centre, Chapel Hill, NC and were cultured in DMEM, 10 % fetal bovine serum. All mammalian cells were grown at 37 o C in a humid environment with 5 % CO 2 and were confirmed to be free of mycoplasma contamination.
Assay of Luciferase Activity
HEL 92.1.7 were co-transfected with various pGL3Basic-recombinant plasmids, encoding firefly luciferase, along with pRL-TK, encoding renilla luciferase, using DMRIE-C® transfection reagent as per as previously described 74 . In the case of the EA.hy 926 cells, in brief, 24 hr prior to transfection cells were plated in 6well format to achieve 60-80 % confluency at time of transfection and were co-transfected with recombinant 
Western Blot Analysis
The expression of Sp1, PU.1 and Oct-1 proteins in HEL cells was confirmed by western blot analysis.
Briefly, whole cell protein was resolved by SDS-PAGE (10 % acrylamide gels) and transferred to polyvinylidene difluoride (PVDF) membrane according to standard methodology. Membranes were screened using anti-Sp1, anti-PU.1, anti-Fli1, anti-Ets-1 and anti-Oct-1 sera in 5 % non fat dried milk in 1 x TBS (0.01 M Tris-HCl, 0.1 M NaCl) for 2 hr at room temperature followed by washing and screening using goat anti-rabbit horseradish peroxidise (sc-2204) followed by chemiluminescence detection. HEL cells transiently co-transfected with pcDNA3, pcDNA3:HaOct-1 and pcDNA3:HaOct-2 were analysed by western blotting (60 µg whole cell protein per lane) using anti-HA 3F10 antibody; to confirm uniform protein loading, the blots were stripped and rescreened with anti-HDJ-2 antibody (Neomarkers) to detect endogenous HDJ-2 protein expression. HEL and EA.hy926 cells transiently co-transfected with pcDNA3, pcDNA3:HaOct-1, pCMVSPORT6-Sp1, pCMVSPORT6-PU.1, pSG5-Fli1 or pSG5-Ets-1 were analysed by western blotting (60 µg whole cell protein per lane) using anti-Oct-1, anti-Sp1, anti-PU.1, anti-Fli1 and anti-Ets-1 antibodies respectively.
Electrophoretic Mobility Shift and Supershift Assays
Nuclear extract was prepared from HEL cells as previously described 74 . Oligonucleotides corresponding to the sense (5′ end-labelled with biotin) and antisense strands of each probe (90 µM) were annealed by heating to 95 o C for 5 min followed by slow cooling to room temperature. Binding reactions were set up by incubating nuclear extract (2 µg total protein) with/without 300-fold molar excesses of non-labelled doublestranded competitors/non-competitors in 1 x Binding Buffer (20 mM Tris-HCl, pH 7.5., 80 mM NaCl, 1 mM EDTA, 100 ng of bovine serum albumin, 25 µg/ml poly(dI-dC), 10% glycerol, 1 mM DTT) for 45 min at room temperature. An appropriate concentration of biotin-labelled probe was then added and incubated for a further 45 min at room temperature after which protein-DNA complexes were then resolved by electrophoresis through 6% nondenaturing polyacrylamide gels. After electrophoresis, the DNA was For electrophoretic mobility supershift assays, nuclear extract (2 µg total protein) was pre-incubated with 3 µg of anti-Sp1, anti-PU.1, anti-Fli1, anti-Ets-1 or anti-Oct-1 sera for 1 hr at room temperature prior to the addition of the relevant biotinylated Sp1 or PU.1/Oct-1 probes.
ChIP analysis
Chromatin immunoprecipitation (ChIP) assays were performed essentially as described by Kock et al., 2007 76 . Briefly, HEL cells (1 x 10 8 ) were grown in RPMI, 10 % FBS to 70 % confluency and collected by centrifugation at 2,000 g for 5 min at 4 o C, washed twice in ice-cold PBS and resuspended in 50 ml serumfree RPMI. EA.hy 926 cells (1 x 10 8 ) were grown in DMEM, 10 % FBS to 70 % confluency and were harvested by scraping and collected by centrifugation at 2,000 g for 5 min at 4 o C, washed twice in ice-cold PBS and resuspended in 50 ml serum-free DMEM.
Formaldehyde ( 
Statistical Analysis
Statistical analysis of differences were analysed using the two-tailed Students' unpaired t-test or, as specifically indicated in the text, using two-way analysis of variance (ANOVA). All values are expressed as mean ± standard error of the mean (SEM). P-values ≤ 0.05 were considered to indicate statistically significant differences and *, **, ***, **** indicate P ≤. 0.05, 0.01, 0.001, 0.0001, respectively.
FIGURES
Figure 1: Effect of 5' and 3' Deletions on PrmIP-directed Gene Expression in HEL 92.1.7 cells.
A schematic of the human prostacyclin receptor (IP) genomic region spanning nucleotides -2427 to +767 encoding PrmIP, in addition to exon (E)1, intron (I)1 and E2 is shown. Nucleotide +1 corresponds to the translational start site (ATG) and nucleotides 5′ or 3' thereof are given a -or + designation, respectively. 
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